Post by
prophetoffactz on May 15, 2023 3:16pm
Moment of truth:
The S&P Biotech ETF is ~10% higher than where it was when the Biodexa agreement was announced. The biotech market is significantly more favorable. Biodexa promoted BTI's licensing deals and Chiesi and the J&J option were probably the reason why. Chiesi now has a strategic position in LSDs given the recent approval of Fabry in the US and Europe. The brain is of strategic interest for LSDs. J&J has advanced and expanded its xB3 deal since the Biodexa deal I believe Rathjen said at the AGM. A multi-product licensing deal with J&J could serve as major validation for xB3. The brain has never been so hot given recent Alzheimer's data and RNAi. BTI was the main attraction by valuation in the Biodexa deal and Midatech secured a financing. BTI's technology could be used with Biodexa's technology. There is also the Neuramedy deal.
We are suppose to get a Saltarelli out of this company. He stayed for a reason. He doesn't have to be here. He's on Chiesi's xB3 Advisory Board. He thinks xB3 works equal to or better than DNLI's technology. With Biodexa they aimed for creating the biggest opportunity for a biotech of its size. The brain is hotter than its ever been given recent advances. There should be $30-$50-$75 million in value in BTI's options in the near term.
Comment by
ROSIE2023 on May 15, 2023 11:22pm
Then why does salty not own any shares ?
Comment by
prophetoffactz on May 16, 2023 5:07am
Same reason the stock is only $.02. It is high risk. He's got stock options. Doesn't change the fact that Saltarelli came. He hasn't left despite career options. Chiesi and the world's largest healthcare company(ie, J&J) are here. Armistice Capital wanted in. Doesn't take much to see the potential for a Saltarelli here.